Methods of treating neurodegenerative disorders in a particular population
AssigneeAlzheon, Inc.
InventorsSusan ABUSHAKRA, Aidan POWER, Martin TOLAR, John HEY, Jeremy YU, Petr KOCIS
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof, based upon a combination of APOE4 status and disease severity.
Claims17
A method of treating Alzheimer's Disease in a subject, the method comprising administering a pharmaceutical composition comprising valyl-3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt thereof to a subject determined to (i) be APOE4 heterozygous and have moderate Alzheimer's Disease;
- or (ii) be APOE4/4 homozygous and have mild or mild-moderate Alzheimer's disease.
A method of treating Alzheimer's Disease in a subject, the method comprising the steps of:
- a. administering a pharmaceutical composition comprising tramiprosate, valyl-3-amino-1-propanesulfonic acid or a pharmaceutically acceptable salt of either of the foregoing to a subject determined to (i) be APOE4 heterozygous and have moderate Alzheimer's Disease;
- or (ii) be APOE4/4 homozygous and have mild or mild-moderate Alzheimer's disease;
- and
- b. not administering, to the subject, the pharmaceutical composition when the subject is determined to be (i) APOE4 negative;
- (ii) APOE4 heterozygous and not suffering from moderate Alzheimer's Disease;
- or (iii) APOE4/4 homozygous and not suffering from mild or mild-moderate Alzheimer's disease.
A method of determining a subject's suitability for treatment with valyl-3-amino-1-propanesulfonic acid, comprising determining the APOE4 status of the subject and the severity of the subject's Alzheimer's disease, wherein if:
- a) the subject is APOE4 heterozygous and has moderate Alzheimer's disease;
- or b) the subject is APOE4/4 homozygous and has mild or mild-moderate Alzheimer's disease, the subject is determined to be suitable for treatment.
A pharmaceutical composition comprising between 260 mg and 270 mg of valyl-3-amino-1-propanesulfonic acid;
- and a pharmaceutically acceptable carrier, wherein the composition is formulated as an instant release, oral tablet or capsule.
Dependencies are inferred from the claim text.